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Treatment-resistant hypertension (TRH) affects between 3 and 30% of hypertensive patients, and its presence is associated with increased
cardiovascular morbidity and mortality. Until recently, the interest on these patients has been limited, because providing care for them is dif-
ficult and often frustrating. However, the arrival of new treatment options [i.e. catheter-based renal denervation (RDN) and baroreceptor
stimulation] has revitalized the interest in this topic. The very promising results of the initial uncontrolled studies on the blood pressure
(BP)-lowering effect of RDN in TRH seemed to suggest that this intervention might represent an easy solution for a complex problem. How-
ever, subsequently, data from controlled studies have tempered the enthusiasm of the medical community (and the industry). Conversely, these
new studies emphasized some seminal aspects on this topic: (i) the key role of 24 h ambulatory BP and arterial stiffness measurement to identify
‘true’ resistant patients; (ii) the high prevalence of secondary hypertension among this population; and (iii) the difficulty to identify those patients
who may profit from device-based interventions. Accordingly, for those patients with documented TRH, the guidelines suggest to refer them to
a hypertension specialist/centre in order to perform adequate work-up and treatment strategies. The aim of this review is to provide guidance
for the cardiologist on how to identify patients with TRH and elucidate the prevailing underlying pathophysiological mechanism(s), to define a
strategy for the identification of patients with TRH who may benefit from device-based interventions and discuss results and limitations of these
interventions, and finally to briefly summarize the different drug-based treatment strategies.
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Introduction
There is wide variability in the reported prevalence of treatment-
resistant hypertension (TRH) with rates from 3 to 30% of hyperten-
sive patients.1–7
Medical care for these patients has been proved to be difficult,
time-consuming, and often frustrating. Accordingly, for those pa-
tients with documented TRH, the guidelines suggest to refer them
to a hypertension specialist/centre in order to perform adequate
work-up and treatment strategies. Although TRH is a relevant prob-
lem associated with significant cardiovascular (CV) morbidity and
mortality (Table 1),8,9 until recently, it received little attention
from the medical establishment. With the advent of catheter-based
renal denervation (RDN), the interest for this high-risk population
has increased dramatically.10 Driven by a medico-industrial complex
and sustained by a large echo in the media, the initially very
promising blood pressure (BP)-lowering effects of TRH in patients
with TRH11,12 were used to suggest that this novel therapeutic op-
tion may represent an easy solution for a complex problem. How-
ever, this overoptimistic view has been tempered by recent data
from controlled studies that failed to demonstrate efficacy of
TRH13 or showed efficacy only in highly selected patients.14
The revitalized scientific interest for this topic has allowed us to
identify several important aspects that need to be considered in the
evaluation and management of patients with TRH. The aim of this
review is to discuss some points that are seminal for the cardiologist,
namely (i) the key role of 24 h ambulatory BP measurement (ABPM)
for the assessment of patients with suspected TRH to rule out white
coat hypertension, confirm the diagnosis, and guide the further
evaluation; (ii) the importance of excluding secondary hypertension
as underlying cause of TRH by appropriate work-up; (iii) evaluate
the presence of vascular remodelling to guide further investigation;
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(iv) define a strategy to identify patients with TRH who may benefit
from device-based interventions; (v) discuss results and limitations
and provide indications for the use of device-based interventions
in TRH; and (vi) briefly summarize the medical treatment for TRH.
Definition and prevalence of
treatment-resistant hypertension
The reported variation in the prevalence of TRH in a general hyper-
tensive patient population is due to differences in the definition of
and in the methods used for the assessment of BP resistance.
According to the most recent European Society of Hypertension/
European Society of Cardiology guidelines on hypertension, TRH is
defined as office systolic BP . 140 mmHg and/or diastolic BP .
90 mmHg despite appropriate life-style measures and antihyperten-
sive treatment including a diuretic (at full dose) and two other
antihypertensive drugs of different classes at adequate doses.7
A drawback of this definition is based on office BP measurements
and, therefore, may result in the inclusion of a significant proportion
of patients with white coat hypertension.
Work-up of patients with
suspected resistant hypertension
Key role of 24 h ambulatory blood
pressure measurement
Rule out white coat hypertension
Given the high prevalence of white coat hypertension in patients
with suspected TRH based on office BP measurements, 24 h
ABPM should be part of the routine work-up (Figure 1). Clinical signs
suggestive of white coat hypertension are high office BP values with-
out signs of target organ damage (discussed subsequently) and the
presence of symptoms associated with hypotension (i.e. dizziness,
fatigue, and blurring) that may be related to antihypertensive over-
treatment. The importance of 24 h ABPM to rule out white coat
hypertension in the setting of suspected TRH is demonstrated by
de la Sierra et al.15 in a large cohort of hypertensive patients. In
this study, the prevalence of TRH based on office BP (systolic office
BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg on three or more
antihypertensive drugs, one of them being a diuretic) was 12.2%. Of
these patients, roughly one-third had white coat hypertension, sug-
gesting that in unselected patients treated for hypertension, the
prevalence of TRH based on 24 h ABPM is ,10%. In line with
this estimation, in a study using 24 h ABPM to determine the eligibil-
ity for catheter-based RDN, the proportion of patients with TRH
was ,10%,16 and a recent survey of a very large population
(.172 000) of patients with hypertension reported a prevalence
of TRH of ,5%.17 Parenthetically, it should be noted here that in-
accurate BP measurement techniques are a common cause of
pseudo-resistance in patients treated for hypertension. Particular at-
tention should be paid to adequate cuff size, because the use of a cuff
size that is too small for the circumference of the arm may result in
the overestimation of BP by .15 mmHg.18
Based on these observations and in accordance with recent
guidelines (i.e. NICE guidelines)19 and other experts in the field,20,21
we deem 24 h ABPM to be mandatory for the diagnosis, risk strati-
fication, and work-up in patients with suspected TRH (Table 2).
Alteration of the dipping status as a clue for the presence
of secondary hypertension
In patients with TRH, the prevalence of secondary hypertension is
significantly higher than that in the general hypertensive popula-
tion.22 This is illustrated by Azizi et al.14 in a cohort of 1416 patients
with TRH who were screened for eligibility of RDN, and of whom
.50% had to be excluded because of the presence of secondary
hypertension.
Twenty-four-hour ABPM allows the assessment of night-time BP.
The absence of a night-time drop (dipping of .10% relative to the
daytime BP) or the increase of BP during night time (‘reverse noctur-
nal dipping’) is often associated with secondary hypertension.22 The
most common causes of secondary hypertension in the context of
treatment resistance and non-dipper status are obstructive sleep ap-
noea (OSA), renal parenchymal and/or vascular disease, and pri-
mary aldosteronism (PA). Screening for these common causes
should be performed as follows (for more detailed information,
see our recent review22).
Rule out secondary hypertension as a
cause of treatment-resistant hypertension
Obstructive sleep apnoea
OSA has been identified as one of the most common causes of sec-
ondary hypertension. Non-dipping or reverse dipping associated
with a history of snoring, daytime sleepiness, and morning headache
should prompt to suspect OSA. Screening for OSA can easily be
done by assessing daytime sleepiness using a questionnaire
(Epworth screening questionnaire) and by home sleep testing using
a portable sleep monitor device. If the latter reveals an increased
apnoea–hypopnoea index (i.e. .5 apnoeas/hypopnoeas per hour
of sleep), the patient should be referred to a specialist for further
evaluation and treatment.
Renal parenchymal or renovascular disease
Screening for renal parenchymal disease should be performed by
urine analysis (protein, erythrocytes, and leucocytes) and measure-
ment of serum creatinine concentration. In the case of a pathological
finding, renal ultrasound should be the next step.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Co-morbidities associated with resistant
hypertension
Co-morbidities Odds ratio (95% CI)
Coronary artery disease 1.3 (1.1–1.5)
Peripheral vascular disease 1.3 (1.1–1.5)
Cerebrovascular disease 1.3 (1.1–1.5)
Congestive heart failure 2.9 (2.4–3.4)
Atrial fibrillation 3.5 (2.0–6.2)
Left ventricular hypertrophy 2.1 (1.2–3.6)
Chronic kidney disease 2.1 (1.8–2.5)
Albuminuria 2.4 (1.7–3.5)
Resistant hypertension 2687
Although in the general hypertensive population the presence of
atherosclerotic renal artery stenosis (RAS) is low (1–8%),23,24 its
prevalence in patients with TRH is much higher (i.e. 15–40%).22
Non-dippers with abrupt progression of the severity of hyperten-
sion or recent renal function deterioration [particularly after
therapy with angiotensin-converting enzyme (ACE)-inhibitors or
angiotensin-receptor blockers] or patients presenting with flash pul-
monary oedema (i.e. Pickering syndrome)25,26 should be screened
for RAS by duplex ultrasound, computed tomography, or magnetic
resonance imagining.
Primary aldosteronism
Primary aldosteronism refers to inappropriately high aldosterone
synthesis that is independent of the renin–angiotensin system and
cannot be suppressed by sodium loading. Clinical signs of PA are
not very specific, and hypokalaemia is present in only 40% of
the patients with confirmed PA. As a first screening step, the plasma
aldosterone–renin ratio (ARR) should be assessed after adequate
preparation of the patient.22 In the case of increased ARR, the pa-
tient should be referred to a hypertension specialist/centre for add-
itional work-up and treatment.
Less common causes of secondary hypertension
For an extensive discussion about screening for less common causes
of secondary hypertension, we refer to our previous review.22
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Value of office, home, and 24 h ambulatory
blood pressure measurement in resistant hypertensive
patients
Significance Office
BP
Home
BP
24 h
ABPM
Diagnosis of resistant hypertension +/2 + +++
Prognostic value +/2 + +++
Exclusion of white coat hypertension 2 +/2 ++
Assessment of therapy adherence 2 +/2 ++
Differentiation primary/secondary
hypertension
+/2 +/2 ++
Figure 1 Work-up of patients with suspected treatment-resistant hypertension. The work-up comprises three main steps: (i) confirmation of
resistant hypertension by 24 h ABPM; (ii) evaluation of night-time BP dipping; and (iii) assessment of vascular stiffness. After confirmation of TRH
by 24 h ABPM and if altered dipping or increased vascular stiffness is present, exclusion of secondary hypertension should be the next step. In
those patients with normal dipping status and 24 h PP, 63 mmHg, carotid-femoral PWV should be measured. If normal (i.e. ,10 m/s), poor
compliance, life-style factors, and interfering substances should be excluded, before searching for secondary hypertension. ABPM, ambulatory
blood pressure measurement; BP, blood pressure; Na+, sodium; LVEF, left ventricular ejection fraction; PWV, pulse-wave velocity; PP, pulse
pressure.
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Evaluate the presence of vascular
remodelling
In the next step, we propose to evaluate the presence of increased ar-
terial stiffness, because in patients with true TRH vascular remodelling
is likely to be present. The gold standard method to non-invasively
assess arterial stiffness is the measurement of carotid-femoral pulse-
wave velocity (PWV).27 This is easily done by using appropriate
devices,28 and normal values have been published.29 Alternatively,
it is often forgotten that pulse pressure (PP ¼ systolic BP – diastolic
BP) is a valid and widely available proxy of vascular stiffness.27
PWV . 10 m/s,29 24 h PP ≥ 63 mmHg,30 or central PP .
55 mmHg31 suggests vascular remodelling. The absence of in-
creased arterial stiffness suggests the presence of pseudo-resistance,
and we suggest to search for poor treatment adherence, life-style
factors known to increase arterial BP, and drugs interfering with
the antihypertensive treatment.
If vascular remodelling is absent, rule out poor treatment
adherence, life-style factors that increase arterial BP, and
substances interfering with efficacy of antihypertensive
treatment
Poor treatment adherence
Non-adherence is one of the most frequent causes of treatment
‘resistance’,32 with up to 50% of the patients with apparent resist-
ance not taking their medication as prescribed, when adherence is
assessed by urine analysis.33 Accordingly, when adherence is moni-
tored, roughly one-third of patients with ‘apparent’ TRH normalize
their BP.34 Several strategies have been proposed to assess and im-
prove therapy adherence, including the measurement of drug con-
centrations in serum or urine, the use of pillboxes recording every
opening event, and specific counselling programmes. This topic has
been recently extensively discussed35 and is beyond the scope of
our article, but as an example, electronic pillboxes have been shown
to improve and normalize BP in roughly 30% of the ‘resistant’ hyper-
tensive patients.34 Performing 24 h ABPM immediately after the
patient has taken his/her antihypertensive drugs in the presence
of a nurse or physician is an easy way to assess the effect of the
prescribed medication.
Rule out life-style factors causing RHT
Life-style modifications reduce BP by 5–10 mmHg in non-selected
hypertensive patients.36 Obesity, excessive salt intake, and alcohol
consumption are frequently associated with TRH.
Obesity. Treatment-resistant hypertension and more severe hyper-
tension are often associated with obesity.37 Underlying mechanisms
contributing to this problem are an increased cardiac output related
to sodium retention and subsequent volume expansion38 and in-
creased sympathetic nervous system (SNS) activity, particularly in
obese patients suffering from concomitant OSA.39 It has to be
kept in mind, however, that in the general hypertensive population,
weight loss is associated with modest BP reduction (i.e. systolic/dia-
stolic BP reduction of 2/1 mmHg per kg of body weight loss),40 and
data on the effect of weight loss on BP in obese patients with TRH
are scarce.37 It appears that interventions targeting simultaneously
several life-style modifications (i.e. weight loss, lower salt, and alco-
hol consumption) are more effective than interventions targeting
each of these factors sequentially.41
Sodium consumption and water retention. Patients with TRH often
are salt-sensitive and are characterized by an increased salt intake
and impaired renal function.42 – 45 Increased sodium consumption
(i.e. .6 g/day) is associated with a gradual rise in BP and CV risk
in normotensive and hypertensive subjects.42 The BP-lowering ef-
fect of decreased sodium consumption is particularly marked in
‘salt-sensitive’ patients with HT (i.e. Africans and East Asians, obese
and elderly of all ethnicities),46 which may be related to the altered
responsiveness of the renin–angiotensin–aldosterone system
(RAAS).42 In patients with TRH, excessive salt intake contributes
importantly to resistance, as shown by a marked decrease in both
office (by 22.7/9.1 mmHg) and 24 h ambulatory BPs (by 20.7/
9.6 mmHg) during dietary sodium restriction in a cross-over study
by Pimenta et al.44 The magnitude of the sodium restriction-induced
decrease of BP is substantially greater in patients with TRH than in
normotensive subjects or general hypertensive patients. This obser-
vation is consistent with the hypothesis that in TRH, excessive so-
dium consumption is a major contributor to treatment resistance,
particularly when associated with increased arterial stiffness.44
The relationship among vascular stiffening, ageing, and volume ex-
pansion is shown in Figure 2:47 with ageing and consequent stiffening
of the vasculature, a small increase in volume is associated with an
exaggerated increase in BP. Thus, vascular remodelling and volume
expansion are two important mechanisms involved in the pathogen-
esis of TRH (Figure 3).
Alcohol consumption. Acute alcohol intake increases BP by sympa-
thetic activation that appears to be centrally mediated.48 Moreover,
chronic heavy alcohol intake (.60 g/day ethanol) increases BP even
in normotensive subjects.48,49 There is, however, little information
on the role of excessive alcohol consumption and the effect of its
reduction in patients with TRH.50
Figure 2 Age dependency of the aortic volume–pressure rela-
tionship. With increasing age, volume expansion results in a mark-
edly larger increase of aortic pressure, reflecting the increasing
vascular rigidity associated with ageing [modified from (37) with
permission].
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Substances or drugs interfering with antihypertensive treatment.
Several substances and drugs can induce arterial hypertension or
interfere with antihypertensive medications. For an extensive dis-
cussion of this topic, we refer to a previous review.51 In the context
of TRH, the potential role of a BP rising effect by non-steroidal anti-
inflammatory drugs (NSAIDs) needs to be considered. NSAIDs
induce sodium and water retention by inhibition of renal prostaglan-
din synthesis as well as other mechanisms. In susceptible patients
(i.e. elderly, salt-sensitive, and pre-existing renovascular disease),
this effect may lead to treatment resistance and/or acute renal fail-
ure. Moreover, NSAIDs may interfere with several important anti-
hypertensive drug classes [ACE-inhibitors, angiotensin-receptor
blockers (ARBs), and b-blockers].
Identification of patients with
treatment-resistant hypertension
who may benefit from device-based
interventions
Patients who remain hypertensive despite treatment with a combin-
ation of ‘A’ (ACE-inhibitor or ARB) with ‘C’ [calcium channel block-
er (CCB)] plus ‘D’ (thiazide-like diuretic, i.e. chlortalidone or
indapamide) at the maximal tolerated dosage and a fourth-line anti-
hypertensive agent (i.e. aldosterone antagonist, discussed subse-
quently) may qualify for a device-based intervention.
With the demonstration of the failure of RDN to lower BP in the
general population of patients with TRH, identification of patients
with TRH who may/may not benefit from device-based intervention
becomes of major importance. In the following, we focus on
sympathetic activation, isolated systolic hypertension (ISH), and ar-
terial remodelling as potential predictors of the success and/or fail-
ure of device-based intervention (Figure 4).
Excessive sympathetic activity does not predict the BP
response to device-based intervention
Excessive activity of the SNS has been suggested to contribute im-
portantly to the sustained BP increase in hypertensive patients.52
This notion was confirmed by Grassi et al.,53 showing marked sym-
pathetic activation and baroreflex dysfunction in TRH. It needs,
however, to be kept in mind that the pathogenic role of sympathetic
activation seems to be most relevant in young (and/or obese) hyper-
tensive patients.52,54 In line with this hypothesis, surgical sympathec-
tomy has been documented to reduce BP and mortality in young
(mean age 42 years) hypertensive patients.55 In contrast, several re-
cent studies refute the hypothesis of a major role of the SNS in the
pathogenesis of TRH in elderly patients,13,56 and BP changes after
RDN were reported to be temporarily, qualitatively, and quantita-
tively independent of sympathetic and baroreflex effects.57 Taken
together, the current evidence suggests that pre-intervention
assessment of sympathetic nerve activity is a poor predictor of BP
response to RDN.
Isolated systolic hypertension, a contraindication
for device-based intervention?
Twenty-four-hour ABPM should be performed to confirm the
presence of therapy resistance (24 h ambulatory pressure .130/
80 mmHg) and to check whether marked ISH (24 h ambulatory
Figure 3 Risk factors and pathogenic mechanisms associated with treatment-resistant hypertension. Risk factors for treatment-resistant hyper-
tension often induce vascular remodelling and volume expansion, two factors known to contribute to resistant hypertension. BP, blood pressure;
Na+, sodium; PWV, pulse-wave velocity; LV, left ventricular; EF, ejection fraction.
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PP ≥ 63 mmHg)30 is present. Systolic and diastolic BPs increase un-
til the age of about 50 years. Thereafter, due to age-related progres-
sive stiffening of the vasculature, systolic BP continues to increase
whereas diastolic BP decreases. This has three important conse-
quences: (i) the proportion of patients with ISH increases with
age, from about 47% in the decade of the 50–59 years old to
.75% a decade later;58 (ii) in people .50 years, systolic BP be-
comes the most important determinant and predictor of CV
risk;59 and (iii) ISH is a marker for increased arterial stiffness (also
discussed subsequently) and has been associated with blunted BP
response to RDN.56 Accordingly, we suggest that the presence of
ISH is a contraindication to device-based interventions.
Pronounced arterial stiffness, a contraindication for
device-based intervention
Advanced vascular remodelling represents a ‘common denomin-
ator’ for ISH, TRH, and poor systolic BP control (Table 3). Most im-
portantly, vascular remodelling is an important factor associated
with a blunted BP-lowering effect of device-based interventions. In
line with this concept, patients with pronounced arterial stiffen-
ing31,60 and/or ISH56 show no or a reduced effect of RDN on BP.
Indeed, in a recent observation, roughly 30% of the patients with
TRH taking six antihypertensive drugs failed to attain target BP va-
lues (home BP ,135/85 mmHg) after RDN.14
Therefore, assessment of arterial stiffness by measuring carotid-
femoral PWV or central PP should be part of the work-up of pa-
tients with TRH before considering device-based interventions.
The presence of exaggerated arterial stiffness (i.e. carotid-femoral
PWV . 10 m/s,29 or 24 h PP . 63 mmHg,30 or central PP .
55 mmHg31) represents a contraindication for device-based
intervention.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Patient characteristics associated with
increased arterial stiffness, resistant hypertension, and
isolated systolic hypertension
Characteristic 
Arterial
stiffness
Resistant
hypertension
Isolated
systolic
hypertension
Older age ++ ++ +++
Poor systolic BP
control
++ ++ +++
Obesity + ++ +/2
Diabetes mellitus + ++ ++
Smoking ++ ++ ++
Vascular
atherosclerosis
++ ++ ++
 Carotid IMT ++ ++ ++
LV hypertrophy ++ +++ +++
Chronic kidney
disease
+++ ++ ++
IMT, intima-media thickness; LV, left ventricle.
Figure 4 Screening for device-based interventions. Patients remaining hypertensive under therapy with the combination A + C + D plus an
aldosterone antagonist should undergo 24 h ABPM and arterial stiffness assessment. If isolated systolic hypertension or increased arterial stiffness
(i.e. carotid-femoral PWV. 10 m/s and/or 24 h PP. 63 mmHg and/or central PP . 55 mmHg) is found, device-based interventions should be
not performed. A, angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker; C, calcium channel blocker; D, thiazide(-like) diur-
etic; ABPM, ambulatory blood pressure measurement; PWV, pulse-wave velocity; PP, pulse pressure.
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Device-based and medical therapy
of patients with resistant
hypertension
Device-based interventions
Attenuation of exaggerated activity of the SNS represents the aim of
device-based interventions (i.e. carotid baroreceptor stimulation
and RDN) for the treatment of TRH. Some (patho)physiological dif-
ferences between these two interventions should, however, be kept
in mind. Although carotid baroreceptor stimulation decreases cen-
tral neural sympathetic outflow through electrical activation of this
sympatho-inhibitory reflexogenic area, RDN decreases sympathetic
over-activity by ablation of renal sympatho-excitatory afferents.
Moreover, carotid baroreceptor stimulation significantly decreases
resting heart rate, whereas RDN has no detectable effect on this
variable.
In the following, we will briefly review the pathophysiological
background and the clinical evidence of these two device-based
therapeutic options.
For an extensive overview on this topic, we refer to a previous
review.61
Carotid baroreceptor stimulation
Electrical stimulation of the carotid baroreceptor(s) causes a sus-
tained reduction of sympathetic outflow and arterial BP in animal
models of hypertension and humans.62– 64 Similarly, in animal mod-
els of obesity-induced hypertension, baroreceptor activation in-
duces a sustained BP decrease through global- and renal-specific
inhibition of SNS activity.65 In contrast, in animal models of angio-
tensin II-induced hypertension and aldosterone hypertension,66
baroreflex-induced reductions in arterial BP are blunted,62,67 sug-
gesting that this intervention may not be very effective in the pres-
ence of high concentrations of angiotensin II or aldosterone. In
humans with TRH, baroreceptor stimulation has been found to de-
crease 24 h ambulatory BP (210/6 mmHg) by reducing central
neural sympathetic outflow and renin release at 4-month follow-
up.68 Interestingly, recent data suggest that unilateral right-sided ca-
rotid baroreceptor stimulation may be more effective than left-
sided or bilateral stimulation in lowering office BP in patients with
TRH.69
The main disadvantages of this technique are the need of surgical
implantation and the lack of data on its effectiveness on CV events.
Therefore, in accordance with recent guidelines, we suggest that
baroreceptor stimulation should be considered in patients with
TRH only after documented failure of adequate drug treatment,
and the implantation of the device should be performed by experi-
enced surgeons in selected hypertension centres (Class IIb, Level
C).7 Moreover, it should be kept in mind that the BP-lowering effect
of baroreceptor stimulation may be attenuated in TRH associated
with hyperaldosteronism.66
Catheter-based renal denervation
The initial enthusiasm for this minimally invasive technique has re-
cently been tempered by the publication of the negative results of
the first randomized SHAM-controlled study.13 As a consequence
of these disappointing results, most industry-sponsored studies
were stopped, and the scientific community has started an intensive
search for possible explanations of this debacle. Table 4 outlines po-
tential factors and co-morbidities that may result in a blunted
BP-lowering effect of RDN in TRH. In the following, we will elabor-
ate a few of them.
Patient-related factors
Vascular remodelling is often present in TRH and may represent an
important factor associated with blunted BP-lowering effect of
RDN. In line with this hypothesis, RDN had little or no BP-lowering
effect in patients with pronounced arterial stiffening31,60 and/or
ISH.56
Another important aspect that needs to be considered is the role
of SNS activation in the pathogenesis of TRH. In the elderly, and pa-
tients of African and East Asian origin (i.e. salt-sensitive populations)
with TRH, increased SNS activity appears to play a minor pathogenic
role. In line with this hypothesis, African and East Asian ethnicities
have been identified as independent predictors of poor BP response
to RDN in the Symplicity HTN-3 trial.70
The anatomy of the renal vasculature has been identified as an-
other relevant factor for patient selection and the subsequent BP re-
sponse to RDN. Roughly 50% of the non-selected patients with
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Potential factors and co-morbidities related
to blunted blood pressure lowering effect of renal
denervation
Patient-related factors
Vascular remodelling (i.e. exaggerated arterial stiffness)
Older age
Presence of isolated systolic hypertension
Increased pulse-wave velocity and increased pulse pressure
Long duration of hypertension
Generalized arteriosclerosis
Smoking and diabetes
Chronic kidney disease
Pathophysiological factors (i.e. exaggerated sympathetic activation
is not a major contributor)
Older age
Ethnicity
Exaggerated salt retention and volume expansion
Anatomical factors
Presence of accessory renal arteries
Secondary renal artery stenosis
Renal sympathetic re-innervation
Medication adherence
Technical factors
Incomplete ablation of the renal nerves
Insufficient number of ablation points
Localization of ablation (should comprise all four quadrants)
Device-related factors
No direct feedback for success of denervation
Insufficient ablation depth
Operator experience
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arterial hypertension do not meet the current anatomical eligibility
criteria for RDN.71– 73 For example, accessory renal arteries appear
to be important for the BP response to RDN, as these arteries,
which often are not accessible to denervation, are surrounded by
sympathetic nerves.74 In line with this hypothesis, in patients with ac-
cessory renal arteries, the BP reduction achieved by RDN is less
pronounced than in patients with bilateral single renal arteries.75
Finally, the so-called ‘Wilder’s principle’ (i.e. the pre-treatment
value determines the magnitude of the post-treatment response)
should be kept in mind, when considering BP responses to an anti-
hypertensive treatment.76 In the context of RDN, different BP
measurement methods (i.e. office BP and 24 h ABPM) have been
used to determine the antihypertensive response. In general, office
BP values often are significantly higher than ambulatory 24 h BP
values. It is not surprising, therefore, that in studies using office BP
measurements (higher pre-treatment valuesgreater post-
treatment effect), the BP-lowering effect of RDN is more
pronounced than in studies using 24 h ABPMs (lower pre-treatment
valuessmaller post-treatment effect).76
Technical factors
As evidenced by the recent failure of RDN to lower BP in TRH13
and the ensuing search for anatomical and technical explanations
for this failure, effective catheter-based RDN is not as simple as it
was initially believed. An extensive discussion on this topic77,78 is be-
yond the scope of this review. Nevertheless, we wish to point out a
few important aspects: first, incomplete ablation of the renal nerves
(i.e. insufficient number of ablation points and/or inadequate local-
ization of ablation) results in a blunted BP-lowering effect.70,74,79– 81
Accordingly, the recent Expert Consensus Guidelines on RDN
recommend four-quadrant ablation in order to obtain sufficient
ablation of renal sympathetic nerves.78,81 Of note, in the Symplicity
HTN-3 trial, only 6% of the patients underwent bilateral
four-quadrant ablation,81 and a high number of ablations and energy
delivery in a four-quadrant pattern were associated with a greater
decrease in office and ambulatory systolic BPs in this trial.70 Secondly,
and along the same lines, no ablation device has a useful direct
feedback system to detect successful ablation, and, as a conse-
quence, operator experience is essential for successful RDN. The
importance of the latter is highlighted by the results of two recent
trials. In the Symplicity HTN-3 trial, .30% of the operators per-
formed only one intervention and only 50% performed more than
two interventions. In the recently published DENERHTN trial,
showing a significant decrease in ambulatory BP in patients treated
with standardized stepped-care antihypertensive medications and
RDN compared with those without RDN,.80% of the procedures
were performed in five centres treating five or more patients.14,82
Finally, it has to be noted that even if (and there still remains an ‘if’)
RDN will be documented to consistently decrease BP, we do not
know whether or not this decrease in BP will translate into a de-
crease in stroke, heart attack, and CV death. Interestingly, data in
apoprotein E knockout mice suggest that RDN may have favourable
CV effects beyond BP lowering as, in this experimental model, RDN
attenuated the progression of atherosclerosis.83
We recommend considering RDN in patients with TRH under
A + C + D plus aldosterone antagonist after exclusion of isolated
systolic HT and increased arterial stiffness. Keeping in mind that
even when fulfilling the abovementioned criteria, salt-sensitive po-
pulations with TRH (i.e. Asians and American Africans) and patients
with accessory renal arteries are expected to respond poorly to
RDN.
Standard medical treatment approach
for treatment-resistant hypertension
The standard medical treatment of TRH has been discussed in detail
by others. Briefly, we recommend the following approach (Figure 5).
Figure 5 Antihypertensive drug therapy in patients with resistant hypertension. We recommend to start with the combination A + C + D. If
the patient remains hypertensive, we recommend a clinical evaluation to determine which one among the three potential pathogenic mechanisms
volume expansion, sympathetic over-activity, and increased arterial stiffness prevails over the others, and to add additional drugs in function of this
evaluation. A, angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker; C, calcium channel blocker; D, thiazide(-like) diuretic;
SNS, sympathetic nervous system.
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First step: A 1 C 1 D
RAAS activation plays an important role in the pathophysiology of
hypertension. In accordance with several guidelines,19,84,85 we rec-
ommend as first step in the treatment of TRH the combination of A
(ACE-inhibitor or ARB) with C (CCB) plus D (thiazide-like diuretic,
i.e. chlortalidone or indapamide) at the maximal tolerated dosage.
This recommendation is based on a pathophysiological rationale.86
The ‘A + C + D’ combination acts on different BP regulatory sys-
tems in a way that both activated and counter-regulatory mechanisms
are inhibited: although all A + C + D promote natriuresis and vaso-
dilation, A inhibits the RAAS and the SNS activated by ‘C + D’.86 Of
note, RAAS activation is often absent in elderly patients and in pa-
tients of African origin in whom a low renin status is frequently
found.87 In line with this observation, sequential nephron blockade
appeared to be more effective than sequential RAAS blockade for
the treatment of TRH,88 suggesting that these patients may be
more sensitive to intensified sodium depletion than to reinforced
RAAS blockade.
In patients with a moderate-to-severe impairment of renal function
[i.e. glomerular filtration rate (GFR) ≤ 45 mL/min/1.73 m2], a shift
from a thiazide(-like) to a loop diuretic should be considered.
Although C strategy is often based on dihydropyridine CCBs (i.e. am-
lodipine, felodipine, lercanidipine, and nifedipine), in some cases (i.e.
increased heart rate), non-dihydropyridine CCBs (i.e. verapamil and
diltiazem) should be considered.
There is sound evidence that ‘A+ C’,89–91 ‘A+ D’,92–94 and ‘C+
D’95 are very effective in reducing hard CV endpoints in hypertensive
patients. Moreover, recent data show that A + C + D is associated
with a significantly greater reduction of all-cause mortality in patients
with TRH and diabetes than ‘A+ Placebo + D’.96 We recommend,
whenever possible, to use single-pill combinations of A + C + D, as
these combinations are more effective in lowering BP,97 have a better
adverse effect profile,98 and improve therapy adherence.98
Second step: clinical evaluation to detect whether a
pathogenic mechanism prevails over others
If the patient under A + C + D is still hypertensive (i.e. office BP.
140/90 mmHg and/or 24 h ABPM. 130/80 mmHg), we recommend
a clinical evaluation to determine whether sodium and water reten-
tion [search for peripheral oedema, increased urinary sodium excre-
tion, increased left ventricular (LV) filling pressures, etc.] or
sympathetic activation and increased arterial stiffness (increased aver-
age heart rate on 24 h ABPM and increased PWV or PP) predominate.
Third step: addition of a fourth-line antihypertensive agent
We recommend different drugs depending on the prevailing patho-
genic mechanism detected during step 2. If volume expansion
predominates, spironolactone (25–50 mg/day) or eplerenone
(50–100 mg/day in the case of gynaecomastia with spironolactone)
should be added.99,100 In the case of increased SNS activity and/or
arterial stiffness, an alpha-blocker (i.e. doxazosin) that may have
favourable effects on BP and vascular remodelling should be
added.101 – 103
Fourth step: addition of a fifth/sixth antihypertensive agent
In the case of persistent volume expansion, we propose to add
(in addition to the thiazide, not instead) a long-acting loop diuretic
(i.e. torasemide). If persistent sympathetic over-activity is suspected,
adding a b-blocker with vasodilator properties (i.e. nebivolol which
is also NO donor) or a combined a-/b-blocker (i.e. carvedilol and
labetalol) should be considered.104 In the case of increased arterial
stiffness, aldosterone antagonists have been shown to have favour-
able effects on BP and vascular remodelling.105 For further steps, see
Figure 5.
Assessment of target organ
damage and co-morbidities in
patients with treatment-resistant
hypertension
Patients with TRH are at high risk for CV morbidity and mortality
and are characterized by an increased prevalence of target organ da-
mages and co-morbidities (Table 1).8,9,106 It is, therefore, important
to search for these problems in order to evaluate the overall CV risk
and to take appropriate measures.7
Cardiac evaluation by echocardiography
Echocardiography allows us to detect morphological alterations
that are common in TRH, such as LV hypertrophy (≥115 g/m2
for men and ≥95 g/m2 for women), left atrial (≥34 mL/m2),
and aortic enlargement,107 and, in patients with cardiac symp-
toms, to search for functional alterations such as LV diastolic
[septal tissue Doppler early diastolic velocity (e′) ,8.0 cm/s]
and/or systolic dysfunction (LV ejection fraction ,55%) and
altered LV filling pressures [increased if transmitral E and septal
e′ (E/e′) ≥13].108
Renal function and (micro)albuminuria
Hypertension-induced renal damage should be searched for by as-
sessment of renal function and by measurement of urinary albumin
excretion. The cut-off value for impaired renal function is an esti-
mated GFR (eGFR),60 mL/min/1.73 m2, and for microalbuminuria
a urinary albumin/creatinine ratio.3.9 mg/g for men and.7.5 mg/g
for women. If excessive salt intake is suspected, assessment of 24 h
urinary Na+ excretion is recommended.
Arteriosclerosis
Generalized arteriosclerosis (i.e. coronary, peripheral, and cere-
brovascular) is a common finding in patients with TRH8 and its
presence is predictive for future CV events.2,109 Physical examin-
ation should therefore at least include fundoscopy (presence of
retinopathy) and the search for carotid, abdominal, and femoral
bruits.
If patients with TRH report symptoms evoking generalized ar-
teriosclerosis (i.e. angina pectoris, claudication, and cerebrovascular
symptoms) and/or the physical examination reveals suspicious signs,
rapid diagnostic work-up (i.e. coronary angiography and duplex of
cerebral and peripheral arteries) should be performed, because
TRH increases the risk for CV disease,4 and if associated with cor-
onary artery disease, it markedly increases CV morbidity and
mortality.1
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Follow-up of patients with
treatment-resistant hypertension
According to the current European guidelines on hypertension, we
recommend 24 h ABPM and assessment of end-organ damage (i.e.
search for arteriosclerosis on physical examination, fundoscopy,
eGFR, albuminuria, and echocardiography) on a yearly basis.7
Conclusions and perspectives
The development of new therapeutic approaches during the last
years awakened the ‘hibernated’ interest on resistant hypertensive
patients. Correct diagnosis of ‘true’ drug resistance through 24 h
ABPM, exclusion of a secondary form of hypertension, and assess-
ment of arterial stiffness are indispensable steps in the work-up. The
different pathogenic mechanisms involved in therapy resistance are
still incompletely understood. Sodium retention and consequent
volume expansion and vascular remodelling appear to play a central
role; however, specific de-stiffening therapeutic strategies are still
under investigation and not available at a large scale.110 Future stud-
ies should elucidate the role of SNS activation in different resistant
hypertensive subpopulations and confirm (rule out) its role as an im-
portant modifiable determinant of CV morbidity and mortality in
these subpopulations. A better understanding of the underpinning
pathogenic mechanisms is expected to result in a more personalized
therapeutic approach. In particular, there is an urgent need to refine
the selection criteria for device-based interventions. Finally, tech-
nical advancements of interventional therapy may result in better
BP control and, in turn, reduce CV morbidity and mortality in this
growing high-risk population.
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